<DOC>
	<DOCNO>NCT02065388</DOCNO>
	<brief_summary>Purpose : Warfarin commonly use oral anticoagulant . This drug inter-individual variability due genetic polymorphism warfarin metabolize enzyme , CYP2C9 warfarin target , VKORC1 . The investigator ' team develop pharmacogenetic dosing algorithm predict patient require warfarin dose , thus could prevent warfarin induced warfarin adverse event . Methods : The investigator recruit patient indication warfarin , genotype VKORC1 CYP2C9 determine hospital verify National Center Genome Medicine . The investigator randomize patient one three arm : 1 . Warfarin dose predict dose algorithm develop International Warfarin pharmacogenetic Consortium ( IWPC ) , 2 . Algorithm develop Taiwan Warfarin Consortium 3 . Standard care . The investigator aim determine whether use genetic dose algorithm lead stable dose safer use drug .</brief_summary>
	<brief_title>Pharmacogenetic Dosing Warfarin</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients must give informed consent complete case report form . Patients must age 20 . Patients clinical indication warfarin therapy prior warfarin treatment . Patients complete informed consent form CRF Patients less age 20 . Patients prior currently warfarin treatment . Patients hemorrhagic tendency hemorrhagic disease define copious bleeding cause viral bacterial infection ; cancer hepatic dysfunction define GOP GPT value three time higher normal value Patients Vitamin K deficiency Female patient currently pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>